StratumSkin science, cited
Ingredient Index

Eczema · Barrier

Tacrolimus

Prescription topical calcineurin inhibitor, 0.03%/0.1%

Overall grade ATypical strength 0.03% (children 2+) or 0.1% (adults), twice daily during a flare6 sources

A prescription non-steroid option that calms the immune overreaction behind eczema without thinning skin, which is why it's often used on the face and eyelids, where long-term steroid use is more of a concern. It stings or burns going on for a lot of people, especially in the first few days, and it carries an FDA boxed warning about a theoretical cancer risk. The largest analyses find no increase in cancer risk overall, but a more specific question, a rare lymphoma subtype in long-term tacrolimus users, is a real signal that isn't fully resolved.

Claim by claim

AEczema, vs potent steroidsRoughly matched medium- to high-potency corticosteroids for clearing eczema across 17 trials and over 5,000 patients.
AApplication-site burningConsistently more burning and stinging than steroids, confirmed repeatedly. Usually eases after the first several days of use.
BCancer risk, overallThe largest analysis to date, 3.4 million patients, found no increase in overall cancer risk with either tacrolimus or pimecrolimus.
CCancer risk, a specific lymphoma subtypeA huge long-term cohort found more cutaneous T-cell lymphoma in adult tacrolimus users than in steroid users, a real, statistically significant signal. Whether it's caused by the drug or by early undiagnosed lymphoma looking like eczema in the first place is genuinely unresolved.

References

  1. Svensson A, Chambers C, Ganemo A, Mitchell SA. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Current Medical Research and Opinion, 2011.ASystematic review, 17 trials, 2,328 children and 2,849 adults·Tacrolimus performed about as well as class I/II and class III corticosteroids. It caused significantly more application-site burning, about three times the rate of a class III steroid in one comparison, but didn't differ meaningfully on other side effects or on how often people stopped treatment.PubMed 21563877DOI 10.1185/03007995.2011.582483
  2. Lax SJ, Van Vogt E, Candy B, et al. Topical anti-inflammatory treatments for eczema: network meta-analysis. Cochrane Database of Systematic Reviews, 2024.ANetwork meta-analysis, 291 trials, 45,846 participants·Tacrolimus 0.1% ranked among the most effective treatments in the network, alongside potent corticosteroids. It also carried higher odds of an application-site reaction than any corticosteroid tier.PubMed 39219446DOI 10.1002/14651858.CD015064.pub2
  3. Devasenapathy N, Chu A, Wong M, et al. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis. The Lancet Child & Adolescent Health, 2022.BMeta-analysis, 110 studies (52 RCTs, 58 nonrandomised), 3.4 million patients·The largest and most current analysis of this question. Overall cancer risk wasn't raised by either drug (absolute risk 4.70 vs 4.56 per 1,000), and tacrolimus specifically tracked almost exactly to no added risk (odds ratio 0.99). Consistent across infants, children and adults. This didn't separately isolate lymphoma or skin cancer, so it settles the overall-cancer question more than it settles the more specific one below.PubMed 36370744
  4. Lam M, Zhu JW, Tadrous M, Drucker AM. Association between topical calcineurin inhibitor use and risk of cancer, including lymphoma, keratinocyte carcinoma, and melanoma: a systematic review and meta-analysis. JAMA Dermatology, 2021.CMeta-analysis, 11 studies, 408,366 patients·Lymphoma risk was higher in calcineurin-inhibitor users than in non-users (relative risk 1.86) and than in topical-steroid users (relative risk 1.35), but the pediatric-only subset didn't reach statistical significance, and overall cancer risk wasn't raised. Didn't reliably separate how much of that lymphoma signal was specific to tacrolimus versus pimecrolimus individually.PubMed 33787818DOI 10.1001/jamadermatol.2021.0345
  5. Arana A, Pottegård A, Kuiper JG, et al. Long-term risk of skin cancer and lymphoma in users of topical tacrolimus and pimecrolimus: final results from the extension of the cohort study JOELLE. Clinical Epidemiology, 2021.CCohort study, roughly 160,000 tacrolimus users and 90,000 pimecrolimus users across adults and children, up to 5–9 years median follow-up·The specific finding behind the lymphoma-subtype caveat: adult tacrolimus users had more cutaneous T-cell lymphoma than steroid users (incidence rate ratio 1.80), a real and statistically significant result in a very large cohort. Every other lymphoma type and melanoma tracked below 1 for tacrolimus. Pimecrolimus users showed a separate, smaller signal for melanoma and non-melanoma skin cancer instead. The authors themselves flag that early, undiagnosed cutaneous lymphoma can look like eczema and get treated as eczema before the lymphoma is caught, which would produce exactly this pattern without the drug causing anything. Children's results were inconclusive, too few events either way.DOI 10.2147/CLEP.S331287
  6. Paller AS, Fölster-Holst R, Chen SC, et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. Journal of the American Academy of Dermatology, 2020.BProspective registry cohort, 7,954 children, 44,629 person-years·Only six confirmed cancers occurred over ten years of follow-up, none of them lymphoma or skin cancer, in line with background rates in matched cancer-registry data. Reassuring for children specifically, and consistent with the JOELLE cohort above finding its clearest signal in adults, not children.DOI 10.1016/j.jaad.2020.03.075

Related condition hubs

EczemaPerioral dermatitisVitiligo

Your turn

Did this hold up? Tell us honestly — especially if it didn’t.

Anonymous. Stored in your browser.

The Sunday study

One paper a week, explained properly

We pick a single new study, tell you what it measured, how many people it measured it in, and whether it should change anything you're doing — plus the two articles we published that week. No panic, and no hype.

We don't recommend products yet. When we do, they'll be things you can actually buy in India, any affiliate link will be labelled as one, and a commission will never buy a recommendation.

One email each Sunday. Unsubscribe in one click.